DR info

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

ACH-0144471
   Achillion Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2017-002674-39-NL   Australia;Belgium;Italy;Netherlands;United States;
      2018   Phase 2   EUCTR2017-002674-39-BE   Australia;Belgium;Italy;Netherlands;United States;
      2018   Phase 2   EUCTR2016-003525-42-NL   Australia;Belgium;Netherlands;
      -   Phase 2   EUCTR2016-003525-42-BE   Australia;Belgium;Netherlands;
   Alexion Pharmaceuticals
      2017   Phase 2   NCT03124368   Australia;Belgium;Netherlands;
ACH-0144471 compresse
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States;
ACH0144471 compresse
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States;
ACTH
   Mayo Clinic
      2009   Phase 1   NCT00805753   Canada;United States;
AP1189
   SynAct Pharma ApS
      2021   Phase 2   EUCTR2020-000971-18-NO   Denmark;Norway;
      2020   Phase 2   EUCTR2020-000971-18-DK   Denmark;
   SynAct Pharma Aps
      2020   Phase 2   NCT04456816   Denmark;
APL-2
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
   Apellis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003767-25-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002637-15-FR   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-002637-15-GB   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 2   NCT03453619   United States;
      -   Phase 3   EUCTR2020-003767-25-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
Abatacept
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States;
Acetaminophen
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Acid mycophenolic (Myfortic)
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT01197040   France;
Acthar
   University of Colorado, Denver
      2019   Phase 3   NCT02683889   United States;
   University of North Carolina, Chapel Hill
      2021   Phase 4   NCT02399462   United States;
Acthar Gel
   Mallinckrodt ARD LLC
      2016   Phase 4   NCT02633046   Argentina;Australia;Canada;Chile;Hong Kong;Mexico;New Zealand;Peru;Puerto Rico;Turkey;United States;
Adalimumab
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States;
   University of Michigan
      2019   Phase 2   NCT04009668   United States;
Adalimumab (Humira)
   North Shore Long Island Jewish Health System
      2005   Phase 1   NCT00193648   United States;
Adoport
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Adrenocorticotrophic hormone ACTH
   University Health Network, Toronto
      2010   Phase 1/Phase 2   NCT01093157   Canada;
Advagraf 0,
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain;
Aliskiren
   Columbia University
      2009   Phase 4   NCT01129557   United States;
   Mayo Clinic
      2010   -   NCT01093781   United States;
   Region Skane
      2020   Phase 2   NCT04183101   Sweden;
Apixaban
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark;
   University of North Carolina, Chapel Hill
      2021   Phase 1   NCT04278729   United States;
Aprovel (150 mg)
   Retrophin, Inc
      2015   -   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy;
      2014   -   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy;
   Retrophin, Inc.
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Italy;
Aprovel 150 mg Tablets
   Retrophin, Inc
      2015   -   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy;
      2014   -   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy;
   Retrophin, Inc.
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Italy;
Atrasentan
   Chinook Therapeutics U.S., Inc.
      2021   Phase 2   NCT04573920   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States;
BCX9930
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05162066   Italy;Spain;
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-005855-19-IT   France;Germany;Italy;Spain;United Kingdom;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-005855-19-ES   France;Germany;Italy;Spain;United Kingdom;
BENLYSTA®
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
BENLYSTA® (belimumab)
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom;
BI 764198
   Boehringer Ingelheim
      2022   Phase 2   NCT05213624   -
BMS-188667
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States;
Bardoxolone methyl capsules
   Reata Pharmaceuticals, Inc.
      2017   Phase 2   NCT03366337   United States;
Basiliximab
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States;
Belimumab
   GlaxoSmithKline
      2013   Phase 2   NCT01762852   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Phase 2   NCT03949855   Canada;United States;
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China;
Benlysta (belimumab)
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom;
Bexsero
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States;
Bleselumab
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States;
CCX140-B
   CHEMOCENTRYX, INC.
      2018   Phase 2   EUCTR2017-003021-15-IT   Australia;Canada;Czechia;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States;
   ChemoCentryx
      2018   Phase 2   NCT03703908   United States;
      2018   Phase 2   NCT03536754   Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom;United States;
   ChemoCentryx, Inc.
      2019   Phase 2   EUCTR2017-003022-32-PL   Canada;France;Poland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003021-15-PL   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003021-15-GB   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003021-15-FR   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States;
CCX168
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-001821-42-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001821-42-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001821-42-GB   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001821-42-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001821-42-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001821-42-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001821-42-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001821-42-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001821-42-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
CDX-1135
   Celldex Therapeutics
      2013   Phase 1   NCT01791686   United States;
CXA-10
   Complexa, Inc.
      2018   Phase 2   NCT03422510   United States;
Ciclofosfamida
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain;
Ciclosporin
   Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine
      2007   Phase 4   JPRN-UMIN000001099   Japan;
Conventional therapy
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China;
Corticosteroid
   National Taiwan University Hospital
      2006   Phase 3   NCT00354731   Taiwan;
CsA
   Department of Nephrology, China-Japan Friendship Hospital
      2014   -   ChiCTR-IPR-14005366   -
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China;
   Shijiazhuang kidney disease hospital Limited company
      2017   -   ChiCTR-IPR-17011386   China;
CyA
   Project team for treatment of refractory nephrotic syndrome
      2004   -   JPRN-C000000369   Japan;
Cyclophosphamide
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy;
   Baoji Central Hospital
      2016   -   ChiCTR-IPR-16008344   China;
   Department of Nephrology, China-Japan Friendship Hospital
      2014   -   ChiCTR-IPR-14005366   -
   Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University
      2019   -   ChiCTR1800019833   China;
   Nanjing University School of Medicine
      2011   -   NCT01451489   China;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 1/Phase 2   NCT00007475   United States;
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China;
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China;
   Sichuan Provincial People's Hospital
      2018   -   ChiCTR1800016140   China;
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China;
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China;
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China;
Cyclophosphamide and steroids
   Radboud University
      1997   Phase 3   NCT00135954   Netherlands;
Cyclosporin
   Assiut University
      2017   Phase 3   NCT03180723   -
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2004   Phase 3   NCT00135811   United States;
Cyclosporin, low dose steroid
   Kyungpook National University
      2011   Phase 3   NCT01282073   Korea, Republic of;
Cyclosporine
   Mayo Clinic
      2011   Phase 2/Phase 3   NCT01180036   Canada;United States;
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China;
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04743739   China;
   Renal Division, Peking University First Hospital
      2017   -   ChiCTR-INR-17012212   China;
   Yokohama city university graduate school of medicine
      2005   -   JPRN-UMIN000004653   Japan;
   Yoshihiko Saito
      2007   -   JPRN-UMIN000000963   Japan;
Cyclosporins
   Guangdong Provincial People's Hospital
      2018   Phase 4   NCT03170323   China;
D-Galactose
   Children's Research Institute
      2009   -   NCT01113385   United States;
DMX-200
   Dimerix Bioscience Pty Ltd
      2022   Phase 3   NCT05183646   Australia;New Zealand;
      2022   Phase 3   EUCTR2021-004174-64-DK   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States;
Dacortín 2,
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain;
Dalteparin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark;
Danicopan
   Alexion Pharmaceuticals
      2018   Phase 2   NCT03459443   Australia;Belgium;Italy;Netherlands;United States;
Danzhu Fuyuan Granule
   Jingqing Hu
      2020   -   NCT04498962   China;
Dapagliflozin
   University Health Network, Toronto
      2015   Phase 4   NCT02585804   Canada;
Daratumumab
   Fernando Fervenza
      2017   Phase 2   NCT03095118   United States;
Dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00004990   United States;
Diphenhydramine
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
ENDOXAN BAXTER*50CPR RIV
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy;
Eculizumab
   Columbia University
      2010   Phase 1   NCT01221181   United States;
   Mario Negri Institute for Pharmacological Research
      2014   Phase 2   NCT02093533   Italy;
Eliquis
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark;
Enalapril
   Region Skane
      2020   Phase 2   NCT04183101   Sweden;
Evolocumab
   Department of Nephrology, Nippon Medical School
      2019   -   JPRN-UMIN000038242   Japan;
Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France;
FCM
   Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000037467   China;
FG-3019
   FibroGen
      2008   Phase 1   NCT00782561   United States;
FK506
   Nanjing University School of Medicine
      2011   -   NCT01451489   China;
   Zhi-Hong Liu, M.D.
      2010   -   NCT01161459   China;
Filgotinib
   Gilead Sciences
      2017   Phase 2   NCT03285711   United States;
Fluvastatin
   Treatment center of kidney disease, 281th hospital of PLA
      2009   Phase 1 study   ChiCTR-TQR-12002602   China;
Fragmin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark;
Fresolimumab
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States;
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States;
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States;
   Genzyme, a Sanofi Company
      2012   Phase 2   NCT01665391   Brazil;Germany;Italy;Spain;United States;
GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy;
GC1008
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States;
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States;
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States;
   Genzyme, a Sanofi Company
      2007   Phase 1   NCT00464321   Germany;Italy;United Kingdom;United States;
GFB-887
   Goldfinch Bio, Inc.
      2020   Phase 2   NCT04387448   United States;
GSK1550188
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom;
GSK1550188 (Belimumab)
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
GZ402669
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States;
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States;
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States;
Galactose
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States;
   North Shore Long Island Jewish Health System
      2008   Phase 1   NCT00816504   United States;
      2008   Phase 1   NCT00816478   United States;
Gazyvaro
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Genoxal
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain;
Gold
   Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University
      2019   -   ChiCTR1900027128   China;
   Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000037467   China;
H.P. Acthar Gel
   Stanford University
      2009   Phase 4   NCT01155141   United States;
Hydroxychloroquine
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China;
   Renal Division, Peking University First Hospital
      2016   -   ChiCTR2100045947   China;
INN not available yet
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-003021-15-PL   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States;
Intravenous (i.v.) methylprednisolone 1000 mg, total 9
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands;
Intravenous injection
   Royan Institute
      2015   Phase 1   NCT02382874   Iran, Islamic Republic of;
Ioexolo
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy;
Iptacopan
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Irbesartan
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03493685   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2014   Phase 2   NCT01613118   Belgium;Czech Republic;Czechia;Italy;United States;
Irbesartan tablets
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States;
Irbesartan tablets (NDC# 31722-729-30 approved in the United states)
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
Jianpixiaozhong particles and Wuse Dietotherapy
   Shanghai University of Traditional Chinese Medicine
      2015   -   NCT02610595   China;
L01XC15
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy;
LIPOSORBER® LA-15
   Kaneka Medical America LLC
      2020   -   NCT04065438   United States;
LIPOSORBER® LA-15 System
   Kaneka Medical America LLC
      2015   -   NCT02235857   United States;
LNP023
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04154787   Argentina;China;Czechia;France;Germany;India;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States;
LT4
   Chidren's Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China
      2020   Phase 0   ChiCTR2000038353   China;
Lanraplenib
   Gilead Sciences
      2017   Phase 2   NCT03285711   United States;
Lansoprazole, amoxicillin, clarithromycin
   Istanbul University
      2006   -   NCT00983034   Turkey;
Lisinopril, losartan, and atorvastatin
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States;
Losartan
   Shanghai University of T.C.M
      2014   -   ChiCTR-TRC-14005064   China;
Losartan Tablets & QingReMoShen Granule
   wanglin
      2011   -   NCT01845688   China;
Losmapimod
   GlaxoSmithKline
      2014   Phase 2   NCT02000440   Canada;United States;
MABTHERA*EV 1FL 50ML
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy;
MEDROL*10CPR DIV
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy;
MMF
   The first affiliated hospital of Zhengzhou University
      2012   -   ChiCTR-INR-15007440   China;
MMF and Dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2004   Phase 3   NCT00135811   United States;
MOR03087
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States;
      2020   Phase 2   EUCTR2020-002985-15-GR   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2020   Phase 2   EUCTR2020-002985-15-GB   Australia;Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2020   Phase 2   EUCTR2020-002985-15-DE   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-NL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-IT   European Union;France;Italy;Netherlands;Spain;United States;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-FR   European Union;France;Netherlands;Spain;United States;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-ES   European Union;France;Netherlands;Spain;United States;
MOR202
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-000835-30-IT   Italy;
   Mario Negri Institute for Pharmacological Research
      2021   Phase 2   NCT04893096   Italy;
   MorphoSys AG
      2021   Phase 2   NCT04733040   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States;
      2020   Phase 2   EUCTR2020-002985-15-GR   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2020   Phase 2   EUCTR2020-002985-15-GB   Australia;Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2020   Phase 2   EUCTR2020-002985-15-DE   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-NL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-IT   European Union;France;Italy;Netherlands;Spain;United States;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-FR   European Union;France;Netherlands;Spain;United States;
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-ES   European Union;France;Netherlands;Spain;United States;
      2019   Phase 1/Phase 2   NCT04145440   Australia;Belgium;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States;
MP and CTX
   Wenhu Liu
      2018   -   NCT03466801   China;
MabThera
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France;
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain;
MabThera 100 mg concentrate for solution for infusion
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
MabThera 500 mg concentrate for solution for infusion
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
Medrol
   Hopital Erasme
      2006   -   EUCTR2005-004460-22-BE   Belgium;
Menveo
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States;
Mesenchymal stem cells
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China;
Methylprednisolone
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy;
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   The First Affiliated Hospital of Dalian Medical University
      2009   -   ChiCTR-ONC-12002809   China;
   Tianjin Hospital
      2004   Phase 0   ChiCTR1900022518   China;
Methylprednisone
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States;
Mizoribine
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000158   Japan;
      2001   -   JPRN-C000000379   Japan;
   Project team for treatment of refractory nephrotic syndrome
      2004   -   JPRN-C000000368   Japan;
   The study group of treatment for aged patients with nephrotic syndrome.
      2012   -   JPRN-UMIN000008919   Japan;
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China;
Mycophenolate Mofetil (MMF)
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States;
Mycophenolate mofetil orally 1000 mg twice a day (BID)
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands;
Mycophenolate mofetil, low dose steroid
   Kyungpook National University
      2011   Phase 3   NCT01282073   Korea, Republic of;
Mycophenolate sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Mycophenolic acid
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Mycophenolic sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Myfortic 180mg Tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Myfortic 360mg Tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Myfortic plus low-dose steroid
   The University of Hong Kong
      2010   Phase 4   NCT01185197   China;
NO
   Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037508   China;
Neoral
   Hopital Erasme
      2006   -   EUCTR2005-004469-40-BE   Belgium;
      2006   -   EUCTR2005-004460-22-BE   Belgium;
OBINUTUZUMAB/ GA101
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy;
OMS721 (narsoplimab)
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States;
Obinutuzumab
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   Mario Negri Institute for Pharmacological Research
      2022   Phase 2   NCT05050214   Italy;
   Mayo Clinic
      2021   Phase 2   NCT04983888   United States;
Obitunuzumab
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy;
Oral Cyclosporine
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States;
Orencia
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States;
Over-encapsulated 75 mg Irbesartan Tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States;
Over-encapsulated Irbesartan
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Over-encapsulated Irbesartan Tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
PF-06730512
   PFIZER INC
      2020   Phase 2   EUCTR2019-003607-35-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Poland;Romania;Slovakia;Spain;United Kingdom;United States;
   Pfizer
      2018   Phase 2   NCT03448692   Canada;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;United Kingdom;United States;
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-003607-35-SK   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003607-35-PL   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003607-35-DE   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003607-35-CZ   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Poland;Romania;Slovakia;Spain;Thailand;United Kingdom;United States;
PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States;
Pegcetacoplan
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
   Apellis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003767-25-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2021   Phase 2   NCT04572854   United States;
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002637-15-FR   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-002637-15-GB   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States;
Pentoxifylline
   National Taiwan University Hospital
      2006   Phase 3   NCT00354731   Taiwan;
Perindopril
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China;
Pirfenidone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 2   NCT00001959   United States;
Plasma exchange
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 1/Phase 2   NCT00007475   United States;
Plasmapheresis
   University of Minnesota
      2019   Phase 3   NCT03763643   United States;
Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Pneumococcal polysaccharide serotype 11 2.2 µg
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Pneumococcal polysaccharide vaccine solution for injection in a vial
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Ponticelli Regimen
   Beijing Friendship Hospital
      2020   Phase 4   NCT04424862   China;
Prednisolone
   Astellas Pharma Korea, Inc.
      2012   Phase 4   NCT01763580   Korea, Republic of;
   Children's Hospital Affiliated to Fudan UniversityNanjing Children's Hospital
      2010   -   ChiCTR-TRC-10000871   China;
   Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
      2007   -   JPRN-UMIN000000621   Japan;
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000158   Japan;
      2001   -   JPRN-C000000379   Japan;
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China;
   The University of Hong Kong
      2010   Phase 4   NCT01185197   China;
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Prednisolone and chlorambucil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China;
Prednisolone and mycophenolate mofetil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China;
Prednisona
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain;
Prednisone
   Affiliated Hospital of Guangdong Medical University
      2020   Phase 0   ChiCTR2100041655   China;
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT03970577   France;
      2009   Phase 3   NCT01197040   France;
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States;
   Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College
      2017   Phase 4   ChiCTR1900027627   China;
   Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2006   -   ChiCTR-OPN-17012789   China;
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2011   -   ChiCTR-TRC-11001454   China;
   Longhua Hospital Affiliated to Shanghai University of TCM
      2008   Phase 1 study   ChiCTR-TRC-08000098   China;
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China;
   Radboud University
      2018   Phase 3   NCT03298698   Netherlands;
   Shanghai Children's Hospital
      2020   Phase 0   ChiCTR2000037014   China;
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China;
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China;
   Treatment center of kidney disease, 281th hospital of PLA
      2009   Phase 1 study   ChiCTR-TQR-12002602   China;
   Wenhu Liu
      2018   -   NCT03466801   China;
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   -   NCT03864250   China;
      2018   -   NCT03549663   China;
   the First Affiliated Hospital of Third Military Medical University
      2018   -   ChiCTR1800014719   China;
Prednisone 0,5 mg/kg orally on alternate days
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands;
Prednisone, FK506, MMF
   Xi’an Jiaotong University College of Medicine
      2009   -   NCT00956059   China;
Prednisone, ciclosporin and mycophenolate mofetil
   Beijing Friendship Hospital
      2020   Phase 4   NCT04424862   China;
Prevenar 13 suspension for injection
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Prograf
   Astellas Pharma Korea, Inc.
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of;
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Propagermanium
   Dimerix Bioscience Pty Ltd
      2018   Phase 2   NCT03649152   Australia;
R-021
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
R3R01
   River 3 Renal Corp.
      2022   Phase 2   NCT05267262   -
RE-021
   Retrophin, Inc
      2015   -   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy;
      2014   -   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy;
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Italy;
      2013   -   NCT01622738   United States;
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
RE-021 (Sparsentan)
   Travere Therapeutics, Inc.
      2014   Phase 2   NCT01613118   Belgium;Czech Republic;Czechia;Italy;United States;
RO0485337
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
RO5072759
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
RTX
   Jiangsu Province People's Hospital
      2021   Phase 4   ChiCTR2100042674   China;
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China;
Repagermanium
   Dimerix Bioscience Pty Ltd
      2022   Phase 3   EUCTR2021-004174-64-DK   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States;
Repository Corticotropin Injection
   Mallinckrodt
      2011   Phase 4   NCT01386554   Canada;Chile;Mexico;Turkey;United States;
Rituximab
   #39
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT03970577   France;
   Assiut University
      2017   Phase 3   NCT03180723   -
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy;
   Cambridge University Hospitals NHS Foundation Trust
      2019   Phase 3   EUCTR2018-004611-50-GB   United Kingdom;
   Centre Hospitalier Universitaire de Nice
      2020   Phase 2   NCT03804359   France;
   Department of Medicine, Kidney Center, Tokyo Women&
   George W. Burke
      2012   Phase 3   NCT01164098   United States;
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2009   Phase 3   EUCTR2008-006750-17-IT   Italy;
   Mario Negri Institute for Pharmacological Research
      2009   Phase 3   NCT00981838   Italy;
   Mayo Clinic
      2013   Phase 2   NCT01573533   Canada;United States;
      2011   Phase 2/Phase 3   NCT01180036   Canada;United States;
      2006   Phase 0   NCT00405340   United States;
      2005   Phase 1   NCT00275613   United States;
      2004   Phase 2/Phase 3   NCT00425217   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Phase 2   NCT03949855   Canada;United States;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2008   Phase 2   NCT00550342   United States;
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04154787   Argentina;China;Czechia;France;Germany;India;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States;
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China;
      2021   Phase 3   NCT04743739   China;
   Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      2020   Phase 4   ChiCTR2000033540   China;
   Radboud University
      2018   Phase 3   NCT03298698   Netherlands;
   The First Affiliated Hospital, Sun Yat-Sen University
      2020   Phase 4   ChiCTR2000040799   China;
   Tokyo Metropolitan Geriatric Hospital
      2016   -   JPRN-UMIN000022150   Japan;
   University of Minnesota
      2019   Phase 3   NCT03763643   United States;
   Xinqiao Hospital
      2020   Phase 4   ChiCTR2000032523   China;
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China;
   s Medical University
Rituximab Infusion
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States;
Rosiglitazone (Avandia)
   North Shore Long Island Jewish Health System
      2005   Phase 1   NCT00193648   United States;
SHR1459 High Dose
   Reistone Biopharma Company Limited
      2021   Phase 2   NCT05136456   China;
SHR1459 Low Dose
   Reistone Biopharma Company Limited
      2021   Phase 2   NCT05136456   China;
SUB08293MIG
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Sirolimus
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2002   Phase 2   NCT00050713   United States;
      2002   Phase 2   NCT00040508   United States;
   Renal Division, Peking University First Hospital
      2017   -   ChiCTR-INR-17012212   China;
Soliris
   IRCCS- Mario Negri Institute
      2014   Phase 2   EUCTR2013-003826-10-IT   Italy;
Solondo
   Astellas Pharma Korea, Inc.
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of;
Sparsentan
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Retrophin, Inc
      2014   -   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy;
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2021   Phase 2   NCT05003986   Poland;Spain;United States;
      2018   Phase 3   NCT03493685   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
Sparsentan/Over-encapsulated Sparsentan tablet
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
Sparsentan/Over-encapsulated Sparsentan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States;
Steroid & Cyclosporin
   Sun Yat-sen University
      2014   Phase 2   NCT02173106   China;
Sulfate
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China;
Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France;
Synacthen Depot
   Radboud University Nijmegen Medical Center
      2008   -   EUCTR2008-001647-19-NL   Netherlands;
TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States;
TRU-015
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 1   NCT00479622   United States;
TRUXIMAB
   CHU de Nice
      2019   Phase 2   EUCTR2018-002476-40-FR   France;
TW
   Nanjing University School of Medicine
      2007   Phase 4   NCT00518219   China;
Tacrolimus
   Astellas Pharma Korea, Inc.
      2012   Phase 4   NCT01763580   Korea, Republic of;
   Baoji Central Hospital
      2016   -   ChiCTR-IPR-16008344   China;
   Children's Hospital, Zhejiang University School of Medicine
      2019   Phase 4   ChiCTR1900022943   China;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain;
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2011   -   ChiCTR-TRC-11001454   China;
   Nanjing University School of Medicine
      2006   -   NCT00302536   China;
      2006   -   NCT00302523   China;
   Second Hospital of Jilin University
      2004   -   ChiCTR-TRC-09000539   China;
   Seoul National University Hospital
      2010   Phase 4   NCT01162005   Korea, Republic of;
   Shenzhen Second People's Hospital
      2020   Phase 4   ChiCTR2000032422   Chiina;
   Sichuan Provincial People's Hospital
      2018   -   ChiCTR1800016140   China;
   Southwest Hospital, the First Affiliated Hospital of Army Medical University
      2020   Phase 4   ChiCTR2000031003   China;
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China;
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China;
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   -   NCT03864250   China;
      2018   -   NCT03549663   China;
   Xinqiao Hospital
      2020   Phase 4   ChiCTR2000032523   China;
   the First Affiliated Hospital of Third Military Medical University
      2018   -   ChiCTR1800014719   China;
Tacrolimus Capsules
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States;
Tacrolimus combined with prednisone
   Peking University
      2004   Phase 2/Phase 3   NCT00362531   -
Tetracosactide hexacetaat
   Radboud University
      2008   Phase 2   NCT00694863   Netherlands;
The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
The Comprehensive Treatment Regimen of Traditional Chinese Medicine
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01799460   China;
The immunosuppressive agents
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01799460   China;
Tripterygium Wilfordii
   Department of Nephrology, Sichuan Provincial People's Hospital
      2021   -   ChiCTR2100048382   China;
Tripterygium wilfordii (TW)
   Nanjing University School of Medicine
      2009   -   NCT00801463   China;
URBASON*IM EV 1F 250MG+1F 5ML
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy;
VB119
   ValenzaBio, Inc.
      2021   Phase 1/Phase 2   NCT04652570   United Kingdom;United States;
VX-147
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   NCT04340362   France;Puerto Rico;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000185-42-GB   France;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000185-42-FR   France;United Kingdom;United States;
VX147
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   EUCTR2020-000185-42-GB   France;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000185-42-FR   France;United Kingdom;United States;
Valsartan
   Columbia University
      2009   Phase 4   NCT01129557   United States;
   Shijiazhuang Nephropathy Hospital
      2017   -   ChiCTR-INR-17012070   China;
   The People's Hospital of Guangxi Zhuang Autonomous Region
      2019   -   ChiCTR1800020241   China;
Vitamin D
   The People's Hospital of Guangxi Zhuang Autonomous Region
      2019   -   ChiCTR1800020241   China;
Voclosporin
   Aurinia Pharmaceuticals Inc.
      2018   Phase 2   NCT03598036   Dominican Republic;United States;
Zestril
   Hopital Erasme
      2006   -   EUCTR2005-004469-40-BE   Belgium;
      2006   -   EUCTR2005-004460-22-BE   Belgium;
LNP023 HYDROCHLORIDE SALT
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2019-001734-34-ES   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;